1. Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. (3rd November 2020) Authors: Luo, Man (Melody); Usmani, Saad Z.; Mateos, Maria‐Victoria; Nahi, Hareth; Chari, Ajai; San‐Miguel, Jesus; Touzeau, Cyrille; Suzuki, Kenshi; Kaiser, Martin; Carson, Robin; Heuck, Christoph; Qi, Ming; Zhou, Honghui; Sun, Yu‐Nien; Parasrampuria, Dolly A. Journal: Journal of clinical pharmacology Issue: Volume 61:Number 5(2021) Page Start: 614 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial. Issue 4 (6th February 2022) Authors: Terpos, Evangelos; Dimopoulos, Meletios A.; Boccadoro, Mario; Delimpasi, Sosana; Beksac, Meral; Katodritou, Eirini; Moreau, Philippe; Pompa, Alessandra; Symeonidis, Argiris; Bila, Jelena; Oriol, Albert; Mateos, Maria‐Victoria; Einsele, Hermann; Orfanidis, Ioannis; Gries, Katharine S.; Fastenau, J... Journal: American journal of hematology Issue: Volume 97:Issue 4(2022) Page Start: 481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. (6th April 2021) Authors: Plesner, Torben; Dimopoulos, Meletios A.; Oriol, Albert; San‐Miguel, Jesus; Bahlis, Nizar J.; Rabin, Neil; Suzuki, Kenshi; Yoon, Sung‐Soo; Ben‐Yehuda, Dina; Cook, Gordon; Goldschmidt, Hartmut; Grosicki, Sebastian; Qin, Xiang; Fastenau, John; Garvin, Wendy; Carson, Robin; Renaud, Thomas; Gries, Ka... Journal: British journal of haematology Issue: Volume 194:Number 1(2021) Page Start: 132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study. (30th July 2020) Authors: Chari, Ajai; Rodriguez‐Otero, Paula; McCarthy, Helen; Suzuki, Kenshi; Hungria, Vania; Sureda Balari, Anna; Perrot, Aurore; Hulin, Cyrille; Magen, Hila; Iida, Shinsuke; Maisnar, Vladimir; Karlin, Lionel; Pour, Ludek; Parasrampuria, Dolly A.; Masterson, Tara; Kosh, Michele; Yang, Shiyi; Delioukina,... Journal: British journal of haematology Issue: Volume 192:Number 5(2021) Page Start: 869 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Issue 6 (June 2021) Authors: Dimopoulos, Meletios A; Terpos, Evangelos; Boccadoro, Mario; Delimpasi, Sosana; Beksac, Meral; Katodritou, Eirini; Moreau, Philippe; Baldini, Luca; Symeonidis, Argiris; Bila, Jelena; Oriol, Albert; Mateos, Maria-Victoria; Einsele, Hermann; Orfanidis, Ioannis; Ahmadi, Tahamtan; Ukropec, Jon; Kampf... Journal: Lancet oncology Issue: Volume 22:Issue 6(2021) Page Start: 801 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma. Issue 5 (28th December 2022) Authors: Dosne, Anne‐Gaelle; Li, Xia; Luo, Man Melody; Nnane, Ivo; Dimopoulos, Meletios A.; Terpos, Evangelos; Sonneveld, Pieter; Kampfenkel, Tobias; Carson, Robin; Amin, Himal; Perez Ruixo, Juan; Zhou, Honghui; Sun, Yu‐Nien; Xu, Yan Journal: British journal of clinical pharmacology Issue: Volume 89:Issue 5(2023) Page Start: 1640 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Issue 8 (4th January 2023) Authors: Dimopoulos, Meletios A.; Oriol, Albert; Nahi, Hareth; San-Miguel, Jesus; Bahlis, Nizar J.; Usmani, Saad Z.; Rabin, Neil; Orlowski, Robert Z.; Suzuki, Kenshi; Plesner, Torben; Yoon, Sung-Soo; Ben Yehuda, Dina; Richardson, Paul G.; Goldschmidt, Hartmut; Reece, Donna; Ahmadi, Tahamtan; Qin, Xiang; G... Journal: Journal of clinical oncology Issue: Volume 41:Issue 8(2023) Page Start: 1590 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. Issue 8 (22nd November 2022) Authors: Sonneveld, Pieter; Chanan-Khan, Asher; Weisel, Katja; Nooka, Ajay K.; Masszi, Tamas; Beksac, Meral; Spicka, Ivan; Hungria, Vania; Munder, Markus; Mateos, Maria-Victoria; Mark, Tomer M.; Levin, Mark-David; Ahmadi, Tahamtan; Qin, Xiang; Garvin Mayo, Wendy; Gai, Xue; Carey, Jodi; Carson, Robin; Spen... Journal: Journal of clinical oncology Issue: Volume 41:Issue 8(2023) Page Start: 1600 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗